Trial Profile
Phase I Trial of the Selective Inhibitor of Nuclear Export, KPT-330, in Relapsed Childhood ALL and AML
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 19 Dec 2023
Price :
$35
*
At a glance
- Drugs Selinexor (Primary) ; Antineoplastics
- Indications Acute biphenotypic leukaemia; Acute myeloid leukaemia; Burkitt's lymphoma; Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 14 Dec 2023 Planned End Date changed from 1 Oct 2023 to 1 Jun 2024.
- 31 Jul 2023 Planned End Date changed from 1 Jun 2023 to 1 Oct 2023.
- 22 Apr 2023 Planned End Date changed from 1 Mar 2023 to 1 Jun 2023.